Bank of Montreal Can raised its stake in Shire PLC (NASDAQ:SHPG) by 16.3% during the 3rd quarter, Holdings Channel reports. The firm owned 24,868 shares of the biopharmaceutical company’s stock after acquiring an additional 3,494 shares during the period. Bank of Montreal Can’s holdings in Shire were worth $4,507,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds also recently made changes to their positions in SHPG. Morgan Stanley boosted its stake in shares of Shire by 25.7% in the second quarter. Morgan Stanley now owns 426,212 shares of the biopharmaceutical company’s stock valued at $71,946,000 after buying an additional 87,126 shares in the last quarter. Omni Partners LLP purchased a new stake in shares of Shire in the second quarter valued at approximately $8,297,000. Canyon Capital Advisors LLC purchased a new stake in shares of Shire in the second quarter valued at approximately $14,686,000. Rehmann Capital Advisory Group boosted its stake in shares of Shire by 226.9% in the second quarter. Rehmann Capital Advisory Group now owns 680 shares of the biopharmaceutical company’s stock valued at $115,000 after buying an additional 472 shares in the last quarter. Finally, GAM Holding AG boosted its stake in shares of Shire by 2,242.5% in the second quarter. GAM Holding AG now owns 46,850 shares of the biopharmaceutical company’s stock valued at $7,908,000 after buying an additional 44,850 shares in the last quarter. Institutional investors own 17.88% of the company’s stock.
SHPG opened at $176.28 on Friday. The company has a current ratio of 1.55, a quick ratio of 1.02 and a debt-to-equity ratio of 0.45. The firm has a market cap of $53.85 billion, a price-to-earnings ratio of 11.64, a PEG ratio of 1.58 and a beta of 1.19. Shire PLC has a one year low of $123.73 and a one year high of $182.36.
Shire (NASDAQ:SHPG) last posted its earnings results on Thursday, November 1st. The biopharmaceutical company reported $3.64 EPS for the quarter, missing the Zacks’ consensus estimate of $3.65 by ($0.01). The firm had revenue of $3.87 billion for the quarter, compared to analysts’ expectations of $3.86 billion. Shire had a return on equity of 13.22% and a net margin of 31.06%. The firm’s revenue for the quarter was up 4.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.81 earnings per share. On average, equities analysts anticipate that Shire PLC will post 15.19 earnings per share for the current year.
SHPG has been the topic of a number of analyst reports. ValuEngine downgraded Shire from a “hold” rating to a “sell” rating in a research note on Thursday, September 6th. Royal Bank of Canada set a $195.00 price target on Shire and gave the company a “buy” rating in a research note on Tuesday, October 23rd. BidaskClub upgraded Shire from a “hold” rating to a “buy” rating in a research note on Wednesday, October 24th. Evercore ISI downgraded Shire from an “outperform” rating to a “market perform” rating and set a $196.00 price target on the stock. in a research note on Tuesday, September 4th. Finally, Berenberg Bank downgraded Shire from a “buy” rating to a “hold” rating in a research note on Friday, September 7th. Eight analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Shire has a consensus rating of “Buy” and a consensus price target of $201.11.
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology.
See Also: Fiduciary
Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.